作者
Marla Dubinsky,James D. Lewis,David T. Rubin,Wai Man Maria Chan,Aisha Vadhariya,Xian Zhou,Deborah L. Fisher,Baojin Zhu
摘要
Background: Crohn’s disease activity index [CDAI] and simple endoscopic score for Crohn’s disease [SES-CD] are commonly used measures to assess disease activity in Crohn’s disease (CD). However, these measures may not fully reflect patient experience. Patient-reported outcomes (PROs) provide patient-centric insights about their symptoms, burden, and quality of life. This analysis explores the correlation between PROs, and PROs with clinical/endoscopic responses in patients with CD. Methods: This retrospective analysis used real-world data from the US-based registry, a multicenter Study of a Prospective Adult Research Cohort with Inflammatory Bowel Disease (SPARC IBD). Adults (≥18 years) diagnosed with CD were enrolled between January 2016 and July 2024. Assessments within 30 days of enrollment included sCDAI (short CDAI), SES-CD, and PROs (abdominal pain [AP], stool frequency [SF], general well-being, bowel urgency [BU] and fatigue) captured via electronic case report forms. Spearman correlation coefficients were used to assess correlations between PROs and clinical and endoscopic indices, categorized as strong (0.70–0.89), moderate (0.40–0.69), weak (0.10–0.39), and negligible (0.0–0.09). Results: Of 3435 patients identified at enrollment, mean (SD) age was 41.0 (14.42) years; 57% were female. Mean (SD) disease duration was 14.9 (11.49) years, and 67% were receiving advanced therapy. Mean (SD) sCDAI score was 151.3 (92.62), clinical remission [sCDAI <150]: 61% [n = 1916], mild disease [sCDAI: 150–219]: 20% [n = 636], moderate [sCDAI: 220–450]: 18% [n = 577], severe [sCDAI >450]: 1% [n = 38]. Mean SES-CD score was 3.5 (5.88). For AP (n = 3310), patients reported no symptoms: 47%, mild: 33%, moderate: 16% and severe AP: 5%. Mean (SD, n = 2468) SF reported was 2.2 (2.91). Responses to the general well-being (n = 3308) question were, being generally well: 57%, slightly under par: 29% and poor, very poor, or terrible: 14%. Of 3306 patients responding to BU questions, 31% reported having no BU, 32% reported mild, 17% moderate, and 15% moderately-severe or severe BU. Among 1461 patients, 51% reported experiencing fatigue. The correlation of BU was moderate with sCDAI (r = 0.51), AP (r = 0.40), SF (r = 0.47) and general well-being (r = 0.42); weak with fatigue (r = 0.31) and negligible with SES-CD (r = 0.09). Fatigue correlated moderately with sCDAI (r = 0.48), AP (r = 0.41), general well-being (r = 0.45); weakly with SF (r = 0.32) and SES-CD (r = 0.11). As components of sCDAI, AP (r = 0.74) and general well-being (r = 0.78) correlated strongly; SF (r = 0.62) correlated moderately with sCDAI. Correlation of SES-CD was weak with AP (r = 0.13), general well-being (r = 0.15) and SF (r = 0.16). General well-being correlated moderately with AP (r = 0.54), and weakly with SF (r = 0.34). Conclusions: Most patients with CD enrolled in SPARC IBD exhibit mildly active disease based on their clinical, endoscopic and patient-reported symptomatic endpoints. However, the observed correlations align with results seen in populations with moderately to severely active CD. Notably, BU and fatigue, which are important symptoms in CD, consistently demonstrated a higher correlation with PROs and sCDAI than with SES-CD. These findings support the use of BU and fatigue as independent, patient-centered measures at the point of care.